Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the US
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
300actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-22 | actual | When the study began enrolling |
| Primary completion | 2026-03-06 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-03-06 | actual | The whole study's end, after follow-up |
| First posted | 2025-11-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Alopecia Areata
Intervention
- Drug: Ritlecitinib
Primary outcomes
what the primary-completion date above is the date OFPatient demographics characteristics: race
measured Baseline
Patient demographics characteristics: sex, age at initial AA diagnosis, geographic location of patient's treating dermatologist, insurance type
measured "Baseline" or "Day 1"
Patient demographics characteristics: age at initial AA diagnosis
measured "Baseline" or "Day 1"
Patient demographics characteristics: geographic location of patient's treating dermatologist
measured "Baseline" or "Day 1"
Patient demographics characteristics: insurance type
measured "Baseline" or "Day 1"
Patient clinical characteristics at initial AA diagnosis: AA disease activity
measured "Baseline" or "Day 1"
Patient clinical characteristics at initial AA diagnosis: SALT score
measured "Baseline" or "Day 1"
Patient clinical characteristics at initial AA diagnosis: dermatology life quality index (DLQI) score
measured "Baseline" or "Day 1"
Patient clinical characteristics at initial AA diagnosis: eyebrow involvement
measured "Baseline" or "Day 1"
Patient clinical characteristics at initial AA diagnosis: eyelash involvement
measured "Baseline" or "Day 1"
Patient clinical characteristics at initial AA diagnosis: beard involvement
measured "Baseline" or "Day 1"
Patient clinical characteristics at initial AA diagnosis: AA involvement at other body locations
measured "Baseline" or "Day 1"
Patient treatment history: Additional treatment classes received during ritlecitinib treatment, additional treatment classes received after discontinuation of ritlecitinib, duration of each treatment class
measured "Day 1 through study completion, a minimum of 6-months follow-up"
Characteristics of ritlecitinib treatment: Total duration of ritlecitinib exposure, reasons for ritlecitinib discontinuation (if ritlecitinib treatment stopped before last known clinic visit),
measured "Day 1 through study completion, a minimum of 6-months follow-up"
Real-world clinical outcomes of ritlecitinib treatment: AA disease activity
measured "Day 1 through study completion, a minimum of 6-months follow-up"
Real-world clinical outcomes of ritlecitinib treatment: SALT score overall change from baseline
measured "Day 1 through study completion, a minimum of 6-months follow-up"
Real-world clinical outcomes of ritlecitinib treatment: SALT score
measured "Day 1 through study completion, a minimum of 6-months follow-up"
Real-world clinical outcomes of ritlecitinib treatment: landmark probabilities of achieving SALT ≤20 and ≤10
measured "Day 1 through study completion, a minimum of 6-months follow-up"
Real-world clinical outcomes of ritlecitinib treatment: landmark probabilities of achieving a sustained SALT response
measured "Day 1 through study completion, a minimum of 6-months follow-up"
Real-world clinical outcomes of ritlecitinib treatment: landmark probabilities of achieving ≥30% SALT score reduction from baseline at 6-, 12-, 18-, and 24-months post-index date
measured "Day 1 through study completion, a minimum of 6-months follow-up"
Real-world clinical outcomes of ritlecitinib treatment: beard involvement
measured "Day 1 through study completion, a minimum of 6-months follow-up"
Real-world clinical outcomes of ritlecitinib treatment: eyebrow and eyelash involvement
measured "Day 1 through study completion, a minimum of 6-months follow-up"
Real-world clinical outcomes of ritlecitinib treatment: AA involvement at other body locations
measured "Day 1 through study completion, a minimum of 6-months follow-up"
Real-world clinical outcomes of ritlecitinib treatment: DLQI score
measured "Day 1 through study completion, a minimum of 6-months follow-up"
Real-world clinical outcomes of ritlecitinib treatment: Patient report of feeling embarrassed or self-conscious because of AA
measured "Day 1 through study completion, a minimum of 6-months follow-up"
Real-world clinical outcomes of ritlecitinib treatment: DLQI score overall change from baseline
measured "Day 1 through study completion, a minimum of 6-months follow-up"
Real-world clinical outcomes of ritlecitinib treatment: patient report of AA affecting social or leisure activities
measured "Day 1 through study completion, a minimum of 6-months follow-up"
Real-world clinical outcomes of ritlecitinib treatment: mental health comorbidities present at last known clinic visit
measured "Day 1 through study completion, a minimum of 6-months follow-up"
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed